Drug Report History #127239
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v25-FR | Version v1-EN | |
|---|---|---|
| Language (Changed) | Updated to: French | Was: English |
| Date Updated (Changed) | Updated to: 2022-02-10 | Was: 2020-10-27 |
| Drug Identification Number | 02229411 | 02229411 |
| Brand name | NAROPIN | NAROPIN |
| Common or Proper name | Naropin® (ropivacaine HCl 2mg/mL 5x200mL SU Polybag®) | Naropin® (ropivacaine HCl 2mg/mL 5x200mL SU Polybag®) |
| Company Name | ASPEN PHARMACARE CANADA INC. | ASPEN PHARMACARE CANADA INC. |
| Ingredients | ROPIVACAINE HYDROCHLORIDE | ROPIVACAINE HYDROCHLORIDE |
| Strength(s) | 2MG | 2MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | EPIDURAL BLOCK/INFILTRATION BLOCK/INFILTRATION EPIDURAL | EPIDURAL BLOCK/INFILTRATION BLOCK/INFILTRATION EPIDURAL |
| Packaging size | 5 PP Polybag | 5 PP Polybag |
| Additional packaging sizes | ||
| ATC code | N01BB | N01BB |
| ATC description | ANESTHETICS, LOCAL | ANESTHETICS, LOCAL |
| Reason for shortage | Shortage of an inactive ingredient or component. | Shortage of an inactive ingredient or component. |
| Anticipated start date | 2020-12-01 | 2020-12-01 |
| Actual start date (Changed) | Updated to: 2020-12-02 | Was: |
| Estimated end date (Changed) | Updated to: 2022-02-11 | Was: 2021-07-01 |
| Actual end date (Changed) | Updated to: 2022-02-08 | Was: |
| Shortage status (Changed) | Updated to: Resolved | Was: Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments (Changed) | Updated to: VR89891CA1 | Was: |
| Health Canada comments |